This may interest some:
The National Institute for Health and Care Excellence has issued a Final Appraisal Document recommending nivolumab, also known as Opdivo®, as the first immuno-oncology monotherapy for the treatment of unresectable advanced, recurrent or metastatic esophageal squamous cell cancer (OSCC) in England, in patients who have previously failed chemotherapy.
“With treatment options limited to chemotherapy, surgery and radiotherapy, NICE’s recommendation is a landmark decision for advancing treatment and care in unresectable advanced oesophageal squamous cell cancer, by providing access to nivolumab to those who urgently need it,”
Noting Efti patents include combination therapy with 'Opdivo', which may be the next stage development for Opdivo in this setting?
This may interest some:The National Institute for Health and...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.005(1.49%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.5¢ | 32.8¢ | $839.2K | 2.469M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 125437 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 85415 | 6 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |